FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Nbix Q1 Tops Estimates, Strategic Acquisition To Boost Rare Disease Portfolio

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Neurocrine delivered strong Q1 2026 results with total sales of $811M (+44% Y/Y), significantly outpacing expectations and reflecting robust momentum across both franchises. INGREZZA maintained market leadership with $656.9M (+20% Y/Y) while CRENESSITY generated $153.3M vs $14.5M in the prior year, establishing meaningful revenue diversification. We believe the successful diversification strategy validates commercial potential in rare endocrine disorders and strengthens NBIX's strategic positioning. Management reaffirmed full-year 2026 INGREZZA guidance of $2.7B-$2.8B, reflecting confidence in continued growth trajectory. The announced $2.9B Soleno acquisition (expected Q2 2026 close) will add VYKAT XR for Prader-Willi syndrome to the rare disease portfolio. With a robust $2.65B cash position and multiple pipeline assets advancing through clinical development, we believe NBIX appears well-positioned to sustain growth momentum while expanding its therapeutic footprint in neuropsychiatry and endocrinology.

Related Articles

Research

Research Alert: Expd: Q1 Results Top Expectations

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EXPD delivered strong Q1 results, with EPS of $1.71 versus $1.47 prior year, significantly beating our $1.37 estimate and $1.33 consensus forecast. Revenue rose 4% to $2.7B from $2.67B, exceeding our $2.59B forecast as Airfreight and Customs strength offset Ocean weakness. Mixed segment performance reflected market bifurcation, with Airfreight revenue surging 14% to $1.03B on favorable pricing while Ocean revenue plummeted 23% to $599M due to capacity oversupply pressuring both pricing and volumes. Management expects global capacity oversupply to persist near-term despite maintaining Ocean profitability. Customs/Other revenue jumped 17% to $1.15B, with double-digit growth across all products, due to hyperscaler and high-value technology customer demand plus tariff complexity. Operating margins reached the company's 30% target despite Middle East disruptions, with productivity gains from 2025 AI and technology investments beginning to materialize.

$EXPD
International

New Zealand's Jobless Rate Falls in March Quarter

New Zealand's seasonally-adjusted unemployment rate fell to 5.3% in the March quarter from 5.4% in the December 2025 quarter, data from Stats NZ showed on Wednesday.The seasonally-adjusted number of unemployed people for the quarter was 163,000, down from 165,000 for the December 2025 quarter.The underutilization rate was unchanged at nearly 13% in the quarter, while the participation rate slid 70.4% from 70.5% in the December 2025 quarter.The seasonally-adjusted employment rate was flat at about 67%.The seasonally adjusted youth not in employment, education, or training (NEET) rate rose to over 14% in the March quarter, up from over 13% in the December 2025 quarter."Women aged 20 to 24 continue to have the highest NEET rate, rising 1.9 percentage points to 20.3% in the March quarter," labor market spokesperson Abby Johnston said.

$^NZ50
Research

Research Alert: Emerson Electric: Fq2 Eps Beats Despite Sales Growth Slowdown

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EMR delivered operating EPS growth of 4% Y/Y to $1.54, though underlying sales growth moderated to 0.5%, impacted by the U.S.-Iran conflict according to management. The beat was supported by share buyback activity. We see 5% underlying orders growth signaling a future recovery, with bookings centered in the high-margin Software & Systems business. Management expects Software segment profitability to enter modest recovery in 2H FY 26. The Software & Systems platform delivered 4% reported growth, with Test & Measurement achieving 16% reported growth, reflecting sustained demand in EMR's growth verticals including semiconductor and aerospace markets. Geographic performance revealed mixed fortunes, with Americas leading growth at 5% Y/Y, while Europe declined 4% and Asia/MEA fell 5%, reflecting broader geopolitical tensions. Adjusted segment EBITA margin compressed 40 bps Y/Y to 27.6% despite favorable mix shift toward higher-margin Software & Systems, with Software margins declining 250 bps to 29.2%.

$EMR